The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Medivir; Medivir; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); chio (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); JPH Clinical Development (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Changhoon Yoo
Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; Roche/Genentech; SERVIER
Research Funding - AstraZeneca; Bayer; Boryung Pharmaceuticals; CKD pharm; Eisai; Lunit; SERVIER
 
Zhenggang Ren
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; Roche
Research Funding - MSD (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Incyte Japan; Lilly Japan; MSD; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Delta-Fly Pharma; Eisai; Fujifilm; J-Pharma; MSD; OncoTherapy Science; Ono Pharmaceutical
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Elevar Therapeutics; Exelixis/Ipsen (Inst); J-Pharma; Kinnate Biopharma; Merck (Inst); Moderna Therapeutics; Regeneron; Tyra Biosciences
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Compass Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); SERVIER (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck
 
Stephen Lam Chan
Honoraria - AstraZeneca; Eisai; MSD; Roche
Consulting or Advisory Role - AstraZeneca; BMS; Eisai; MSD Oncology; Roche
Research Funding - Eisai; MSD
Travel, Accommodations, Expenses - Ipsen; Roche
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Bayer; BeiGene; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Incyte; Ipsen; Merck Serono; MSD; Roche; SERVIER; Taiho Oncology
Research Funding - Beigene (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Exeliom Biosciences
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Heinz-Josef Klümpen
Consulting or Advisory Role - AstraZeneca (Inst); Janssen (Inst)
Research Funding - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; ITM Isotope Technologies Munich; Roche
 
Thomas Yau
Honoraria - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb
 
Chris Verslype
Consulting or Advisory Role - Bayer; Ipsen; Roche; SERVIER
Speakers' Bureau - BAYER
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; Ipsen; Servier
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; Eisai; MSD; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Mohamed Bouattour
Honoraria - Bayer Schering Pharma
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Roche; SIRTEX Medical
Research Funding - AstraZeneca (Inst); Bayer Schering Pharma (Inst); BMS GmbH & Co. KG (Inst); Incyte (Inst); Merck (Inst); MSD (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Ipsen; Roche
 
Joon Oh Park
Consulting or Advisory Role - ABL Bio; Adicet Bio; Arcus Biosciences; AstraZeneca; Celgene; ImmuneOncia; Intocell; MediRama; Merck Serono; SERVIER
Research Funding - ABL Bio; Celgene; Eutilex; medpacto; SERVIER
Travel, Accommodations, Expenses - Minneamrita Therapeutics
 
Arndt Vogel
Honoraria - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Pharma GmbH; Boston Scientific; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; GlaxoSmithKline; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Sirtex Medical; Taiho Oncology; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Boehringer Pharma GmbH; BTG; Daichi-Sankyo; EISAI; Incyte; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Taiho Oncology; Taiho Oncology; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Lilly; MSD; Roche
 
Juan W. Valle
Consulting or Advisory Role - Aptitude Health; AstraZeneca; Autem Medical; Baxter; Boehringer Ingelheim; Cantargia AB; Debiopharm Group; Delcath Systems; Genoscience Pharma; Hutchison MediPharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Medivir; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Sirtex Medical; Taiho Oncology; Wren Laboratories; Zymeworks
Speakers' Bureau - Delcath Systems; Imaging Equipment Limited; Incyte; Ipsen; Mylan; Novartis; Nucana; SERVIER
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Lilly; Nucana; Roche
 
Liis Starkopf
Employment - Merck
Stock and Other Ownership Interests - Merat and Co., Inc.
 
Usha Malhotra
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Abby B. Siegel
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Shukui Qin
No Relationships to Disclose